Overview

A Study of Atezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomized study to evaluate the efficacy and safety of atezolizumab compared with platinum-based chemotherapy consisting of a platinum agent (carboplatin or cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel (squamous disease) in highly PD-L1 expressed, chemotherapy-naïve, EGFR/ALK wild type patients with stage IV non-squamous or squamous NSCLC.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Atezolizumab
Carboplatin
Gemcitabine
Paclitaxel
Pemetrexed